Ruben is the scientific founder and CSO of Sapreme with previous experience as CSO of a biotech company developing antibodies and small molecules for anti-angiogenic tumor therapies. Before, he worked as a postdoctoral researcher at The Netherlands Cancer Institute (NKI-AVL) on the molecular mechanisms that regulate cell-matrix interaction and holds a PhD in the field of cardiovascular development and genetics from the Hubrecht Institute.